Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 37 to 44 of 44 entries
Sorted by: Best Match Show Resources per page
Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections.

Molecular therapy : the journal of the American Society of Gene Therapy

Stief TA, Kaeuferle T, Müller TR, Döring M, Jablonowski LM, Schober K, Feucht J, Dennehy KM, Willier S, Blaeschke F, Handgretinger R, Lang P, Busch DH, Feuchtinger T.
PMID: 34058386
Mol Ther. 2021 May 29; doi: 10.1016/j.ymthe.2021.05.021. Epub 2021 May 29.

Viral infections cause life-threatening disease in immunocompromised patients and especially following transplantation. T cell receptor (TCR) engineering redirects specificity and can bring significant progress to emerging adoptive T cell transfer (ACT) approaches. T cell epitopes are well described, although...

Cite
Stief TA, Kaeuferle T, Müller TR, et al. Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. Mol Ther. 2021;doi: 10.1016/j.ymthe.2021.05.021.
Stief, T. A., Kaeuferle, T., Müller, T. R., Döring, M., Jablonowski, L. M., Schober, K., Feucht, J., Dennehy, K. M., Willier, S., Blaeschke, F., Handgretinger, R., Lang, P., Busch, D. H., & Feuchtinger, T. (2021). Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. Molecular therapy : the journal of the American Society of Gene Therapy, . https://doi.org/10.1016/j.ymthe.2021.05.021
Stief, Tanja A, et al. "Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections." Molecular therapy : the journal of the American Society of Gene Therapy vol. (2021). doi: https://doi.org/10.1016/j.ymthe.2021.05.021
Stief TA, Kaeuferle T, Müller TR, Döring M, Jablonowski LM, Schober K, Feucht J, Dennehy KM, Willier S, Blaeschke F, Handgretinger R, Lang P, Busch DH, Feuchtinger T. Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. Mol Ther. 2021 May 29; doi: 10.1016/j.ymthe.2021.05.021. Epub 2021 May 29. PMID: 34058386.
Copy Download .nbib Format: NLM
Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies.

Molecular and cellular pediatrics

Antony JS, Dewerth A, Haque A, Handgretinger R, Kormann MS.
PMID: 26589812
Mol Cell Pediatr. 2015 Dec;2(1):11. doi: 10.1186/s40348-015-0022-6. Epub 2015 Nov 20.

BACKGROUND: The immunogenicity and limited stability of conventional messenger RNA (mRNA) has traditionally restricted its potential therapeutic use. In 1992, the first clinical application of mRNA was reported as a potential protein-replacement therapy; however, subsequent investigations have not been...

Cite
Antony JS, Dewerth A, Haque A, et al. Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies. Mol Cell Pediatr. 2015;2(1):11doi: 10.1186/s40348-015-0022-6.
Antony, J. S., Dewerth, A., Haque, A., Handgretinger, R., & Kormann, M. S. (2015). Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies. Molecular and cellular pediatrics, 2(1), 11. https://doi.org/10.1186/s40348-015-0022-6
Antony, Justin S, et al. "Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies." Molecular and cellular pediatrics vol. 2,1 (2015): 11. doi: https://doi.org/10.1186/s40348-015-0022-6
Antony JS, Dewerth A, Haque A, Handgretinger R, Kormann MS. Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies. Mol Cell Pediatr. 2015 Dec;2(1):11. doi: 10.1186/s40348-015-0022-6. Epub 2015 Nov 20. PMID: 26589812; PMCID: PMC4654728.
Copy Download .nbib Format: NLM
Eradication of pulmonary aspergillosis in an adolescent patient undergoing three allogeneic stem cell transplantations for acute lymphoblastic leukemia.

Case reports in transplantation

Döring M, Zierl A, Mezger M, Lang P, Handgretinger R, Müller I.
PMID: 23259137
Case Rep Transplant. 2012;2012:672923. doi: 10.1155/2012/672923. Epub 2012 Aug 30.

Systemic fungal infections are a major cause of infection-related mortality in patients with hematologic malignancies. This report addresses the case of an adolescent patient with acute lymphoblastic leukemia who underwent three allogeneic hematopoietic stem cell transplantations and developed pulmonary...

Cite
Döring M, Zierl A, Mezger M, et al. Eradication of pulmonary aspergillosis in an adolescent patient undergoing three allogeneic stem cell transplantations for acute lymphoblastic leukemia. Case Rep Transplant. 2012;2012:672923doi: 10.1155/2012/672923.
Döring, M., Zierl, A., Mezger, M., Lang, P., Handgretinger, R., & Müller, I. (2012). Eradication of pulmonary aspergillosis in an adolescent patient undergoing three allogeneic stem cell transplantations for acute lymphoblastic leukemia. Case reports in transplantation, 2012672923. https://doi.org/10.1155/2012/672923
Döring, Michaela, et al. "Eradication of pulmonary aspergillosis in an adolescent patient undergoing three allogeneic stem cell transplantations for acute lymphoblastic leukemia." Case reports in transplantation vol. 2012 (2012): 672923. doi: https://doi.org/10.1155/2012/672923
Döring M, Zierl A, Mezger M, Lang P, Handgretinger R, Müller I. Eradication of pulmonary aspergillosis in an adolescent patient undergoing three allogeneic stem cell transplantations for acute lymphoblastic leukemia. Case Rep Transplant. 2012;2012:672923. doi: 10.1155/2012/672923. Epub 2012 Aug 30. PMID: 23259137; PMCID: PMC3505948.
Copy Download .nbib Format: NLM
Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial.

Leukemia

Sauer MG, Lang PJ, Albert MH, Bader P, Creutzig U, Eyrich M, Greil J, Gruhn B, Holter W, Klingebiel T, Kremens B, von der Leyen H, Mauz-Körholz C, Meisel R, Mischke K, Müller I, Niemeyer CM, Peters C, Pohler C, Reinhardt D, Burkhardt B, Schlegel PG, Schulz AS, Schrum J, Sedlacek P, Strahm B, Woessmann W, Handgretinger R, Zimmermann M, Borkhardt A.
PMID: 31578451
Leukemia. 2020 Feb;34(2):613-624. doi: 10.1038/s41375-019-0584-8. Epub 2019 Oct 02.

AML SCT-BFM 2007 was the first hematopoietic stem cell transplantation (HCT) trial in Germany to comply with the European Clinical Trials Directive, and aimed to standardize pediatric HCT for acute myeloid leukemia (AML) across centers in Germany, Austria, and...

Cite
Sauer MG, Lang PJ, Albert MH, et al. Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial. Leukemia. 2019;34(2):613-624doi: 10.1038/s41375-019-0584-8.
Sauer, M. G., Lang, P. J., Albert, M. H., Bader, P., Creutzig, U., Eyrich, M., Greil, J., Gruhn, B., Holter, W., Klingebiel, T., Kremens, B., von der Leyen, H., Mauz-Körholz, C., Meisel, R., Mischke, K., Müller, I., Niemeyer, C. M., Peters, C., Pohler, C., Reinhardt, D., Burkhardt, B., Schlegel, P. G., Schulz, A. S., Schrum, J., Sedlacek, P., Strahm, B., Woessmann, W., Handgretinger, R., Zimmermann, M., & Borkhardt, A. (2020). Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial. Leukemia, 34(2), 613-624. https://doi.org/10.1038/s41375-019-0584-8
Sauer, Martin G, et al. "Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial." Leukemia vol. 34,2 (2020): 613-624. doi: https://doi.org/10.1038/s41375-019-0584-8
Sauer MG, Lang PJ, Albert MH, Bader P, Creutzig U, Eyrich M, Greil J, Gruhn B, Holter W, Klingebiel T, Kremens B, von der Leyen H, Mauz-Körholz C, Meisel R, Mischke K, Müller I, Niemeyer CM, Peters C, Pohler C, Reinhardt D, Burkhardt B, Schlegel PG, Schulz AS, Schrum J, Sedlacek P, Strahm B, Woessmann W, Handgretinger R, Zimmermann M, Borkhardt A. Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial. Leukemia. 2020 Feb;34(2):613-624. doi: 10.1038/s41375-019-0584-8. Epub 2019 Oct 02. PMID: 31578451.
Copy Download .nbib Format: NLM
[No title available]

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Zhang Y, Kupferschlaeger J, Lang P, Reischl G, Handgretinger R, la Fougere C, Dittmann H.
PMID: 34049985
J Nucl Med. 2021 May 28; doi: 10.2967/jnumed.120.261854. Epub 2021 May 28.

The tumor-selective ganglioside antigene GD2 is frequently expressed on neuroblastomas and to a lesser extent also on sarcomas and neuroendocrine tumors. Aim of our study was to evaluate tumor targeting and biodistribution of iodine-131-labeled chimeric GD2-antibody clone 14/18 (

Cite
Zhang Y, Kupferschlaeger J, Lang P, et al. . J Nucl Med. 2021;doi: 10.2967/jnumed.120.261854.
Zhang, Y., Kupferschlaeger, J., Lang, P., Reischl, G., Handgretinger, R., la Fougere, C., & Dittmann, H. (2021). . Journal of nuclear medicine : official publication, Society of Nuclear Medicine, . https://doi.org/10.2967/jnumed.120.261854
Zhang, Ying, et al. "." Journal of nuclear medicine : official publication, Society of Nuclear Medicine vol. (2021). doi: https://doi.org/10.2967/jnumed.120.261854
Zhang Y, Kupferschlaeger J, Lang P, Reischl G, Handgretinger R, la Fougere C, Dittmann H. . J Nucl Med. 2021 May 28; doi: 10.2967/jnumed.120.261854. Epub 2021 May 28. PMID: 34049985.
Copy Download .nbib Format: NLM
Correction: Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial.

Leukemia

Sauer MG, Lang PJ, Albert MH, Bader P, Creutzig U, Eyrich M, Greil J, Gruhn B, Holter W, Klingebiel T, Kremens B, von der Leyen H, Mauz-Körholz C, Meisel R, Mischke K, Müller I, Niemeyer CM, Peters C, Pohler C, Reinhardt D, Burkhardt B, Schlegel PG, Schulz AS, Schrum J, Sedlacek P, Strahm B, Woessmann W, Handgretinger R, Zimmermann M, Borkhardt A.
PMID: 31768014
Leukemia. 2020 May;34(5):1486. doi: 10.1038/s41375-019-0648-9.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Cite
Sauer MG, Lang PJ, Albert MH, et al. Correction: Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial. Leukemia. 2020;34(5):1486doi: 10.1038/s41375-019-0648-9.
Sauer, M. G., Lang, P. J., Albert, M. H., Bader, P., Creutzig, U., Eyrich, M., Greil, J., Gruhn, B., Holter, W., Klingebiel, T., Kremens, B., von der Leyen, H., Mauz-Körholz, C., Meisel, R., Mischke, K., Müller, I., Niemeyer, C. M., Peters, C., Pohler, C., Reinhardt, D., Burkhardt, B., Schlegel, P. G., Schulz, A. S., Schrum, J., Sedlacek, P., Strahm, B., Woessmann, W., Handgretinger, R., Zimmermann, M., & Borkhardt, A. (2020). Correction: Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial. Leukemia, 34(5), 1486. https://doi.org/10.1038/s41375-019-0648-9
Sauer, Martin G, et al. "Correction: Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial." Leukemia vol. 34,5 (2020): 1486. doi: https://doi.org/10.1038/s41375-019-0648-9
Sauer MG, Lang PJ, Albert MH, Bader P, Creutzig U, Eyrich M, Greil J, Gruhn B, Holter W, Klingebiel T, Kremens B, von der Leyen H, Mauz-Körholz C, Meisel R, Mischke K, Müller I, Niemeyer CM, Peters C, Pohler C, Reinhardt D, Burkhardt B, Schlegel PG, Schulz AS, Schrum J, Sedlacek P, Strahm B, Woessmann W, Handgretinger R, Zimmermann M, Borkhardt A. Correction: Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial. Leukemia. 2020 May;34(5):1486. doi: 10.1038/s41375-019-0648-9. PMID: 31768014.
Copy Download .nbib Format: NLM
Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections.

Molecular therapy : the journal of the American Society of Gene Therapy

Stief TA, Kaeuferle T, Müller TR, Döring M, Jablonowski LM, Schober K, Feucht J, Dennehy KM, Willier S, Blaeschke F, Handgretinger R, Lang P, Busch DH, Feuchtinger T.
PMID: 34058386
Mol Ther. 2022 Jan 05;30(1):198-208. doi: 10.1016/j.ymthe.2021.05.021. Epub 2021 May 29.

Viral infections cause life-threatening disease in immunocompromised patients and especially following transplantation. T cell receptor (TCR) engineering redirects specificity and can bring significant progress to emerging adoptive T cell transfer (ACT) approaches. T cell epitopes are well described, although...

Cite
Stief TA, Kaeuferle T, Müller TR, et al. Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. Mol Ther. 2021;30(1):198-208doi: 10.1016/j.ymthe.2021.05.021.
Stief, T. A., Kaeuferle, T., Müller, T. R., Döring, M., Jablonowski, L. M., Schober, K., Feucht, J., Dennehy, K. M., Willier, S., Blaeschke, F., Handgretinger, R., Lang, P., Busch, D. H., & Feuchtinger, T. (2022). Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. Molecular therapy : the journal of the American Society of Gene Therapy, 30(1), 198-208. https://doi.org/10.1016/j.ymthe.2021.05.021
Stief, Tanja A, et al. "Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections." Molecular therapy : the journal of the American Society of Gene Therapy vol. 30,1 (2022): 198-208. doi: https://doi.org/10.1016/j.ymthe.2021.05.021
Stief TA, Kaeuferle T, Müller TR, Döring M, Jablonowski LM, Schober K, Feucht J, Dennehy KM, Willier S, Blaeschke F, Handgretinger R, Lang P, Busch DH, Feuchtinger T. Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. Mol Ther. 2022 Jan 05;30(1):198-208. doi: 10.1016/j.ymthe.2021.05.021. Epub 2021 May 29. PMID: 34058386.
Copy Download .nbib Format: NLM
Introducing isotonic fluids into pediatric oncology.

Pediatric hematology and oncology

Heinz AT, Eichholz T, Queudeville M, Hartmann U, Ott A, Heinzel O, Handgretinger R, Ebinger M.
PMID: 34752206
Pediatr Hematol Oncol. 2021 Nov 09;1-8. doi: 10.1080/08880018.2021.1996494. Epub 2021 Nov 09.

No abstract available.

Cite
Heinz AT, Eichholz T, Queudeville M, et al. Introducing isotonic fluids into pediatric oncology. Pediatr Hematol Oncol. 2021;1-8doi: 10.1080/08880018.2021.1996494.
Heinz, A. T., Eichholz, T., Queudeville, M., Hartmann, U., Ott, A., Heinzel, O., Handgretinger, R., & Ebinger, M. (2021). Introducing isotonic fluids into pediatric oncology. Pediatric hematology and oncology, 1-8. https://doi.org/10.1080/08880018.2021.1996494
Heinz, Amadeus T, et al. "Introducing isotonic fluids into pediatric oncology." Pediatric hematology and oncology vol. (2021): 1-8. doi: https://doi.org/10.1080/08880018.2021.1996494
Heinz AT, Eichholz T, Queudeville M, Hartmann U, Ott A, Heinzel O, Handgretinger R, Ebinger M. Introducing isotonic fluids into pediatric oncology. Pediatr Hematol Oncol. 2021 Nov 09;1-8. doi: 10.1080/08880018.2021.1996494. Epub 2021 Nov 09. PMID: 34752206.
Copy Download .nbib Format: NLM
Showing 37 to 44 of 44 entries